**Name of journal: World Journal of Hepatology**

**ESPS Manuscript NO: 13988**

**Columns: TOPIC HIGHLIGHTS**

WJH 5th Anniversary Special Issues (6): Liver transplantation

**From minimal to maximal surgery in the treatment of hepatocarcinoma: A review**

Perini MV *et al.*Treatment of hepatocarcinoma

Marcos Vinicius Perini, Graham Starkey, Micheal A Fink, Ramesh Bhandari, Vijayaragavan Muralidharan, Robert Jones, Christopher Christophi

**Marcos Vinicius Perini, Graham Starkey, Micheal A. Fink, Ramesh Bhandari, Vijayaragavan Muralidharan, Robert Jones, Christopher Christophi,** University of Melbourne Department of Surgery, Austin Health, Heidelberg VIC 3084, Australia

**Author contributions:** Perini MV designed the review, collected data, wrote the manuscript; Starkey G reviewed the manuscript; Fink M, Bhandari R, Muralidharan V, Jones R and Christophi C reviewed the manuscript.

**Correspondence to: Marcos Vinicius Perini, MD, PhD,** University of Melbourne Department of Surgery, Austin Health, 145 Studley Road, Level 8, Heidelberg, VIC 3084, Australia. marcos.perini@unimelb.edu.au

**Telephone:** +61-422-493101 **Fax:** +61-394-963670

**Received:** September 11, 2014 **Revised:** October 28, 2014

**Accepted:** November 17, 2014

**Published online:**

**Abstract**

Hepatocellular carcinoma represents one of the most challenging frontiers in liver surgery. Surgeons have to face a broad spectrum of aspects, from the underlying liver disease to the new surgical techniques. Safe liver resection can be performed in patients with portal hypertension and well-compensated liver function with a 5-year survival rate of 50%, offering good long-terms results in selected patients. With the advances in laparoscopic surgery, major liver resections can be performed with minimal harm, avoiding the wound and leak complications related to the laparotomies. Studies have shown that oncological margins are the same as in open surgery. In patients submitted to liver resection (either laparoscopic or open) who experience recurrence, re-resection or salvage liver transplantation has been showing to be an alternative approach in well selected cases. The decision making approach to the cirrhotic patient is becoming more complex and should involve hepatologists, liver surgeons, radiologists and oncologists. Better understanding of the different risk factors for recurrence and survival should be aimed in these multidisciplinary discussions. We here in discuss the hot topics related to surgical risk factors regarding the surgical treatment of hepatocellular carcinoma: anatomical resection, margin status, macrovascular tumor invasion, the place of laparoscopy, salvage liver transplantation and liver transplantation.

© 2014 Baishideng Publishing Group Inc. All rights reserved.

**Key words:** Hepatectomy; Liver resection; Cirrhosis; Liver transplantation; Hepatocelullar carcinoma; Survival

**Core tip:** The decision making approach to the cirrhotic patient with hepatocellular carcinoma (HCC) represents one of the most challenging frontiers in liver surgery and, as a result, should involve a multidisciplinary assessment. Despite the advances in non-surgical therapies, surgery is still the treatment that can offer the best survival. In patients submitted to liver resection who experience recurrence, re-resection or salvage liver transplantation has been shown to be an alternative approach in well-selected cases. We herein discuss some controversial topics regarding the surgical treatment of HCC: anatomical resection, margin status, macro-vascular invasion, laparoscopic resection, salvage liver transplantation and liver transplantation.

Perini MV, Starkey G, Fink MA, Bhandari R, Muralidharan V, Jones R, Christophi C. From minimal to maximal surgery in the treatment of hepatocarcinoma: A review. *World J Hepatol* 2014; In press

**INTRODUCTION**

Hepatocellular carcinoma (HCC) is the most common primary liver cancer and the fifth most common malignancy worldwide[[1](#_ENREF_1),[2](#_ENREF_2)]. In about 90% of cases, it occurs in patients with chronic liver disease[[2](#_ENREF_2),[3](#_ENREF_3)]. In recent years there has been a clear increase in the number of new cases of HCC due to Hepatitis B and C infection[[3](#_ENREF_3),[4](#_ENREF_4)].

Although focal ablation techniques can treat small HCCs, the only curative therapeutic options available are surgical resection (SR) and liver transplantation (LT). Controversial aspects regarding to the surgical treatment of HCC include the extent of resection, whether it should be achieved by laparoscopic or open approach and their impact on subsequent LT. The question of resection or transplantation and the impact of laparoscopic liver resection (LLR) needs to be addressed. We here in discuss the role of laparoscopic (minimal) and open liver resection and liver transplantation (maximal) in the treatment of HCC carcinoma in cirrhotic patients.

**LIVER RESECTION**

Liver resection, a therapeutic alternative that can be performed readily and with lower costs when compared to liver transplantation, is a safe procedure with mortality rates in specialized centers lower than 5%[[5](#_ENREF_5)]. Survival after liver resection can reach 40%-60% in Eastern and Western series[[6](#_ENREF_6)], but recurrence is still a major problem. Recurrence occurs in the liver in around 50%-80% of the cases, being consequence of metastatic spread from the tumor removed or “de novo” occurrence due to underlying liver disease[[7-9](#_ENREF_7)].

In the context of a rising incidence of HCC and a shortage of cadaveric donors, there is a growing discrepancy between the number of transplant candidates on waiting lists and the organs available for transplantation. This shortage can lead to long waiting times, increasing the risk of tumor progression and waiting list drop out[[10](#_ENREF_10)]. Studies comparing resection and transplantation for HCC have often analyzed only those patients who underwent transplantation – ignoring those patients who dropped off the waiting list due to tumor progression. This approach will tend to produce results in favor of transplantation. To be fair, an intention to treat analysis should be performed[[11](#_ENREF_11)].

Resection has the advantages of being readily accessible and cheaper when compared to transplantation and doesn’t preclude a future liver transplant in the case of tumor recurrence (salvage LT). Moreover, due to advances in surgical technique (mainly laparoscopic approach), care and patient selection, it has become a safe procedure, with mortality rates in specialized centers lower than 5%[[12](#_ENREF_12),[13](#_ENREF_13)]. Good long-term results can be achieved (50%-70% 5-year overall survival) in selected patients[[14](#_ENREF_14)].

However, resection is followed by high rates of morbidity and mortality in patients with chronic liver disease, being possible only in patients with preserved liver function[[15](#_ENREF_15)]. In the context of long transplant waiting lists, some groups specialized in both liver surgery and transplantation have advocated resection for the treatment of solitary HCC in patients with preserved liver function[[14](#_ENREF_14),[16](#_ENREF_16)].

It has also been shown that in patients within the Milan criteria, the long-term outcome of those listed for liver transplantation (intention to treat analysis) was similar when compared to patients who underwent resection[[17](#_ENREF_17)]. A recent meta-analysis including studies using case controlled and intention to treat analysis showed that resection and transplantation lead to similar 5y overall survival (OR = 0.84, 95%CI: 0.48-1.48, *P* = 0.45)[[18](#_ENREF_18)].

***Laparoscopic versus open liver resection***

Laparoscopic liver resection (LLR) is now considered the gold standard by many specialized hepatobiliary teams for the treatment of selected cases of benign and malignant liver tumors. Its feasibility and safety are reproducible by teams all over the world[[19](#_ENREF_19)]. Recent series of laparoscopic resection of HCC have shown excellent short and ling long terms results[[16](#_ENREF_16),[20-29](#_ENREF_20)]. A recent meta-analyses showed that LLR resulted in to shorter hospital stay, decreased blood loss, and lower rates of postoperative morbidity (specially ascites and pulmonary complications) when compared to open liver resection[[12](#_ENREF_12),[16](#_ENREF_16),[21](#_ENREF_21),[22](#_ENREF_22)].

Despite selection bias in the laparoscopic group, rates of positive margins after LLR were lower than or similar to those after open approach[[30](#_ENREF_30)]. An increase in peritoneal carcinomatosis and port site recurrence does not seem to have been a major issue[[18](#_ENREF_18)]. Finally, in all studies comparing laparoscopic and open LR for HCC, there was no significant difference in recurrence free and overall survival, suggesting that LLR does not compromise oncological principles.

***Anatomical versus non-anatomical resections***

LR for HCC can be either anatomical (lobectomy, segmentectomy) or non-anatomical (wedge resection, subsegmental resection). In HCC, intrahepatic metastasis occurs mainly through the portal tract, and may be present before surgery. It has been proposed that the intrahepatic spread of hepatic tumors follows the pattern of step-by-step intrahepatic dissemination[[31](#_ENREF_31)]. With small tumors and early metastases, satellite nodules usually lie in the same segment of the main tumor. The anatomical approach is particularly important for the purpose of reducing postoperative intrahepatic tumor recurrence rates.

Anatomical resection, when possible, should be performed[[32](#_ENREF_32)]. A recent study using meta-regression analysis indicated that the 5-year overall survival and disease-free survival are significantly better with anatomical resection[[33](#_ENREF_33)]. Recent paper including 543 patients treated with HCC addressing this issue concluded that anatomical resection can lead to a lower recurrence rate in patients presenting tumors with unfavorable features (poorly differentiated and with vascular invasion), suggesting that the higher the invasiveness of the tumor, the greater the need for the removal of the entire liver functional unit[[34](#_ENREF_34)].

On the other hand, when dealing with cirrhotic patients, leaving sufficient residual liver volume is critical. For small liver HCCs, non-anatomical resection can be carried out without impact on the overall survival[[35](#_ENREF_35)]. The rationale for this approach is that it may lead to a decrease in the rate of postoperative liver failure and that for small lesions, the risk of local satellites or local portal venous invasion is lower than for lesions more than 5 cm in diameter[[36](#_ENREF_36)].

***Margin status***

The optimal resection margin for HCC remains controversial. In a randomized trial comparing a wide 2 cm margin with a margin aiming for 1 cm, improved recurrence-free and overall survival were observed in the wide margin group. However, it is accepted that a 1 cm surgical margin is adequate for the majority of patients with HCC[[37](#_ENREF_37)]. On the other hand, other authors found that a minimal resection margin (surgical margin less than 1 mm) did not negatively affect postoperative recurrence-free survival[[37](#_ENREF_37)]. In a recent meta-analysis, Zhou *et al*[[38](#_ENREF_38)]showed no differences in surgical margins when comparing the open with the LLR group.

Surgeons who are less familiar with liver surgery may be inclined to perform less radical resections. This may represent a lost opportunity for some patients who may have had better long-term prognoses with more radical surgery. In order to minimize the risk of local recurrence and maximize the overall survival chance, a surgical strategy that supports the preference for anatomical and adequate resection with free margins should be adopted whenever possible.

***Repeated liver resection***

Although not properly addressed in a prospective trial, repeated hepatic resection in patients with solitary liver recurrence resulted in better survival than palliative treatment (37%-86% in 5 years)[[39](#_ENREF_39)]. The resectability rate varies and depends on the extent of primary resection and the functional status of the remnant liver[[40](#_ENREF_40)] and even repeated laparoscopic resection can be carried out in selected patients[[41](#_ENREF_41)]. Poor prognostic factors associated with repeated liver resection for HCC are: vascular invasion in the primary surgery, short recurrence interval, tumor size, gender, estimated blood loss[[39](#_ENREF_39),[40](#_ENREF_40),[42](#_ENREF_42)].

***Vascular invasion***

Vascular invasion is a well-defined prognostic factor for overall and disease free survival in patients with HCC either submitted to resection or transplantation[[43](#_ENREF_43),[44](#_ENREF_44)]. Macrovascular invasion is considered a formal contra-indication to resection and invariably patients with macrovascular invasion submitted to LT suffer from recurrence. As proposed by the BCCL, patients with macrovascular invasion are sent for palliative treatment (Sorafenib) or best supportive care[[43](#_ENREF_43),[44](#_ENREF_44)]. Overall survival for patients with portal vein invasion or hepatic vein invasion is 2.7 mo and 5 mo, respectively. The overall survival for patients treated with Sorafenib is 6 mo[[43-45](#_ENREF_43)].

Although not universally accepted, liver resection for HCC with macrovascular invasion may be an option in highly selected patients, in whom a survival of around 10% in 5 year can be offered. Equivalent survival is not achievable with other forms of treatment. In recent surgical series including HCC patients with macrovascular invasion, the postoperative mortality and morbidity ranges from 3.4% to 7.7% and from 30.8% to 37.1%, respectively[[46](#_ENREF_46)]. In a multicentric study on 102 HCC patients with macrovascular invasion treated by surgical resection, Pawlik *et al*[[47](#_ENREF_47)] reported a 5-year survival rate of 10%.

Chok *et al*[[46](#_ENREF_46)]described the following three approaches for patients with portal vein thrombus based on the extension of the tumor thrombosis: group 1, HCC with ipsilateral portal vein tumor thrombus resected in a hepatectomy; group 2, HCC with portal vein tumor thrombus extending to or beyond the portal vein bifurcation, treated by en bloc resection followed by portal vein reconstruction; group 3, portal vein tumor trombosis extending to or beyond the portal vein bifurcation, treated by thrombectomy. The short and long-term results were similar among the three groups with a 5-year overall survival rate of 11.2%, 12.5% and 14.3%, respectively[[46](#_ENREF_46)].

After HCC resection, the hepatic remnant is the most common site of tumor recurrence ranging from 68% to 91% of patients so a close follow up strategy should be adopted[[48](#_ENREF_48)]. While macroscopic vascular invasion can be detected at imaging, microscopic vascular invasion is impossible to visualize before operation. The presence of microvascular invasion can only be confirmed by histological examination of resected specimen.

**LIVER TRANSPLANTATION**

Liver transplantation has become a standard procedure adopted worldwide in the treatment of end stage liver disease with remarkable good results, even for malignancy (1 year overall survival of > 80% and 5y around 70%)[[49](#_ENREF_49)]. LT has the advantage of removing the previous and potential carcinogenic diseased liver but has the disadvantage of organ allocation.

***Liver transplantation versus liver resection***

The choice between liver transplantation (LT) and resection (LR) is controversial and there are no controlled trials comparing these modalities. Although some can argue that resection is cost effective when compared with LT[[50](#_ENREF_50)], only LT has the advantage of simultaneously treating the tumor and the underlying liver disease[[51](#_ENREF_51)]. To achieve good results with transplantation, it is only offered to patients with liver only disease fulfilling strict criteria[[51-53](#_ENREF_51)]. There is considerable variation around the world in what criteria are used to assess transplant eligibility[[52-55](#_ENREF_52)].

For many patients with cirrhosis and HCC, the ideal treatment is transplantation-treating the underlying liver condition and at the same time removing the tumor. This also reduces the “*de novo*” formation of cancer. It is crucial to be selective in choosing patients with HCC for transplantation, with many criteria in use around the world. Most criteria use radiological parameters such as tumor size and number as a surrogate marker for biological behavior[[52](#_ENREF_52),[54-60](#_ENREF_54)]

Unfortunately many patients are delisted for transplantation due to progression of the underlying liver disease or tumor progression (beyond the accepted criteria). When comparing survival between LT and LR, many studies have commenced at the time of the transplant and fail to include analysis of the patients removed from the waiting list due to tumor progression (*i.e.,* not an intention to treat analysis). For optimal evaluation of the treatment effect of LT, the waiting time on the list should be included.

Llovet *et al*[[45](#_ENREF_45)] found a dropout probability of 23%. This resulted in a reduction of 2-year overall survival from 84% to 54%. Waitlist time can serve as a selection period for patients with the best prognosis, because only patients with stable disease undergo transplantation. This might explain the higher recurrence-free survival after LT than in resected patients who did not undergo this selection process. Another reason for better overall survival in different studies might be that LT represents a cure for the underlying cirrhosis, which is the main risk factor for development of HCC. The recurrence rate is higher after LR than OLT. Given the shortage of deceased donor organs, transplantation for resectable HCC may be considered by some groups an inappropriate use of a precious resource if LR alone in selected cases could achieve a similar overall survival, and together with salvage LT may cure recurrence[[18](#_ENREF_18)].

For patients with HCC beyond transplant criteria, the Barcelona Clinic Liver Cancer (BCLC) system recommends palliative treatment[[61](#_ENREF_61)]. Although this system is widely accepted, if followed strictly there are patients who may be denied a curative liver resection and treated with palliative intent with trans-arterial chemoembolization. Many studies criticizing this policy have shown 5 year overall survival of 50% even in patients with large HCC or in patients with multiple nodules[[62](#_ENREF_62)].

Ruzzenente *et al*[[63](#_ENREF_63)] conducted a study on 464 HCC patients from a multi-institutional database and found that patients with fewer than three nodules who underwent LR had a higher survival rate than those who were treated with local therapies [including percutaneous ablation and transarterial chemo-embolization (TACE)] with median survival of 58 and 20 mo (*P* < 0.01), respectively. These findings were confirmed by a subsequent randomised controlled trial. In patients with HCC meeting Milan Criteria, the authors reported a 5-year survival rate after liver resection and radiofrequency ablation of 69% and 45% (*P* = 0.042), respectively[[64](#_ENREF_64)].

A Japanese national survey reported that liver resection has an advantage over local ablative therapies because it can prevent recurrence in individuals with fewer than three HCC nodules that are ≤ 3 cm[[65](#_ENREF_65)]. Liver resection also appears to provide better long-term survival than percutaneous ablation in patients with less than 3 HCC nodules that are > 3 cm.

In selected patients with multinodular BCLC B (more than 3 nodules) HCC and preserved liver function, LR yielded better long-term results than TACE with 5-year survival rates of 36%-37% and 11%-14%, respectively[[62](#_ENREF_62)]

***Salvage liver transplantation***

The major drawback of LR is a recurrence rate of about 40% in the first year[[66](#_ENREF_66)]. Despite this, most authors have shown that those patients can be referred for salvage liver transplantation[[67-70](#_ENREF_67)]. With this strategy, HCC patients who had undergone liver resection with pathological parameters at higher risk of recurrence (*i.e.,* microvascular invasion, satellite nodules) could enter the waiting list for liver transplantation directly without waiting for evidence of HCC liver recurrence[[71](#_ENREF_71)]. On the other hand, Fuks *et al*[[72](#_ENREF_72)] have shown in 329 transplantable patients enrolled in a intention to treat study that the presence of ≥ 3 poor prognostic factors (from a list of microscopic vascular invasion, presence of satellite nodules, tumor size > 3 cm, poor tumoral differentiation, and existence of cirrhosis) should warrant LT before recurrence. This strategy seemed to save 26 grafts that would otherwise have been used unnecessarily. However only 28% of patients included in intention-to-treat analysis and only 39% of patients with recurrence could receive ST, suggesting that tissue analysis should be used as selection criteria for salvage liver transplantation[[72](#_ENREF_72)]. Whether this policy is clinically effective and would further improve the long-term outcomes of resected patients remains to be evaluated in prospective trials.

Belghiti and colleagues showed that patients submitted to salvage transplantation have the same long-term results as those submitted to transplantation as the primary treatment[[73](#_ENREF_73)]. Indeed, Cherqui *et al*[[74](#_ENREF_74)] have shown that 77% of patients with recurrent HCC following LLR were transplantable (within Milan criteria). The same group found that the morbidity of salvage LT for HCC was lower following LLR, than open LR[[75-77](#_ENREF_75)]. Some surgeons argue that adhesion formation and previous hilar manipulation associated with LR can make subsequent LT difficult or even impossible. However, strategies such as Glissonian approach and the use of Pringle maneuver and intraparenchymal access to liver pedicles to avoid hilar manipulation can be employed in order to decrease the morbidity of repeat liver surgery. The use of anti-adhesive products (Seprafilm**®**) although proved to facilitate bowel surgery[[78](#_ENREF_78)] have not been addressed in a randomized trial for liver surgery.

The impact of laparoscopic liver resection versus open resection on subsequent liver transplantation has not yet been analysed in prospective trials. Theoretical advantages of minimal dissection are less adhesions, minimal manipulation in liver hilum and decreased blood loss[[79-81](#_ENREF_79)].

**CONCLUSION**

The main endpoint in the surgical treatment of HCC is to resect the tumor and at the same time preserve remnant liver function. This should be performed with refined techniques and respecting the oncological principals of any cancer surgery. Liver resection and liver transplantation are the only curative treatment of HCC. Meanwhile, there are some strategies to increase resectability or to downstage the tumor, such PVE, TACE or RFA/PEI. Laparoscopic liver resection has gained acceptance and decreases post-operative complications (less ascites and wound related problems). Surgeons can improve disease-free survival by preventing recurrence adopting many strategies, such as > 1 cm surgical margin, anatomical resection encompassing portal area of tumor, using an anterior approach to minimize the risk of tumor cell dissemination, minimizing intraoperative blood loss. Repeat resection is an option in some suitable cases that can be used in the armamentarium of liver surgeons. Salvage transplantation should be offered in non aggressive tumors that recur after liver resection and may improve survival rates. Future clinical research should reveal the optimal combination of therapies in properly selected patients.

**REFERENCES**

1 **Bosch FX**, Ribes J, Díaz M, Cléries R. Primary liver cancer: worldwide incidence and trends. *Gastroenterology* 2004; **127**: S5-S16 [PMID: 15508102]

2 **El-Serag HB**. Hepatocellular carcinoma: recent trends in the United States. *Gastroenterology* 2004; **127**: S27-S34 [PMID: 15508094]

3 **Rahbari NN**, Mehrabi A, Mollberg NM, Müller SA, Koch M, Büchler MW, Weitz J. Hepatocellular carcinoma: current management and perspectives for the future. *Ann Surg* 2011; **253**: 453-469 [PMID: 21263310 DOI: 10.1097/SLA.0b013e31820d944f]

4 **Davila JA**, Morgan RO, Shaib Y, McGlynn KA, El-Serag HB. Hepatitis C infection and the increasing incidence of hepatocellular carcinoma: a population-based study. *Gastroenterology* 2004; **127**: 1372-1380 [PMID: 15521006]

5 **Fan ST**, Mau Lo C, Poon RT, Yeung C, Leung Liu C, Yuen WK, Ming Lam C, Ng KK, Ching Chan S. Continuous improvement of survival outcomes of resection of hepatocellular carcinoma: a 20-year experience. *Ann Surg* 2011; **253**: 745-758 [PMID: 21475015 DOI: 10.1097/SLA.0b013e3182111195]

6 **Pawlik TM**, Esnaola NF, Vauthey JN. Surgical treatment of hepatocellular carcinoma: similar long-term results despite geographic variations. *Liver Transpl* 2004; **10**: S74-S80 [PMID: 14762844 DOI: 10.1002/lt.20052]

7 **Belghiti J**, Panis Y, Farges O, Benhamou JP, Fekete F. Intrahepatic recurrence after resection of hepatocellular carcinoma complicating cirrhosis. *Ann Surg* 1991; **214**: 114-117 [PMID: 1714267]

8 **Arii S**, Tanaka J, Yamazoe Y, Minematsu S, Morino T, Fujita K, Maetani S, Tobe T. Predictive factors for intrahepatic recurrence of hepatocellular carcinoma after partial hepatectomy. *Cancer* 1992; **69**: 913-919 [PMID: 1310434]

9 **Huang ZY**, Liang BY, Xiong M, Zhan DQ, Wei S, Wang GP, Chen YF, Chen XP. Long-term outcomes of repeat hepatic resection in patients with recurrent hepatocellular carcinoma and analysis of recurrent types and their prognosis: a single-center experience in China. *Ann Surg Oncol* 2012; **19**: 2515-2525 [PMID: 22395985 DOI: 10.1245/s10434-012-2269-7]

10 **Llovet JM**, Burroughs A, Bruix J. Hepatocellular carcinoma. *Lancet* 2003; **362**: 1907-1917 [PMID: 14667750 DOI: 10.1016/S0140-6736(03)14964-1]

11 **Schlansky B**, Chen Y, Scott DL, Austin D, Naugler WE. Waiting time predicts survival after liver transplantation for hepatocellular carcinoma: a cohort study using the United Network for Organ Sharing registry. *Liver Transpl* 2014; **20**: 1045-1056 [PMID: 24838471 DOI: 10.1002/lt.23917]

12 **Simillis C**, Constantinides VA, Tekkis PP, Darzi A, Lovegrove R, Jiao L, Antoniou A. Laparoscopic versus open hepatic resections for benign and malignant neoplasms--a meta-analysis. *Surgery* 2007; **141**: 203-211 [PMID: 17263977 DOI: 10.1016/j.surg.2006.06.035]

13 **Sarpel U**, Hefti MM, Wisnievsky JP, Roayaie S, Schwartz ME, Labow DM. Outcome for patients treated with laparoscopic versus open resection of hepatocellular carcinoma: case-matched analysis. *Ann Surg Oncol* 2009; **16**: 1572-1577 [PMID: 19259738 DOI: 10.1245/s10434-009-0414-8]

14 **Silva MF**, Sapisochin G, Strasser SI, Hewa-Geeganage S, Chen J, Wigg AJ, Jones R, Saraiva R, Kikuchi L, Carrilho F, Fontes PR, Charco R. Liver resection and transplantation offer similar 5-year survival for Child-Pugh-Turcotte A HCC-patients with a single nodule up to 5 cm: a multicenter, exploratory analysis. *Eur J Surg Oncol* 2013; **39**: 386-395 [PMID: 23375469 DOI: 10.1016/j.ejso.2012.12.011]

15 **Santambrogio R**, Kluger MD, Costa M, Belli A, Barabino M, Laurent A, Opocher E, Azoulay D, Cherqui D. Hepatic resection for hepatocellular carcinoma in patients with Child-Pugh's A cirrhosis: is clinical evidence of portal hypertension a contraindication? *HPB* (Oxford) 2013; **15**: 78-84 [PMID: 23216782 DOI: 10.1111/j.1477-2574.2012.00594.x]

16 **Herman P**, Perini MV, Coelho FF, Kruger JA, Lupinacci RM, Fonseca GM, Lopes Fde L, Cecconello I. Laparoscopic resection of hepatocellular carcinoma: when, why, and how? A single-center experience. *J Laparoendosc Adv Surg Tech A* 2014; **24**: 223-228 [PMID: 24568364 DOI: 10.1089/lap.2013.0502]

17 **Pelletier SJ**, Fu S, Thyagarajan V, Romero-Marrero C, Batheja MJ, Punch JD, Magee JC, Lok AS, Fontana RJ, Marrero JA. An intention-to-treat analysis of liver transplantation for hepatocellular carcinoma using organ procurement transplant network data. *Liver Transpl* 2009; **15**: 859-868 [PMID: 19642139 DOI: 10.1002/lt.21778]

18 **Proneth A**, Zeman F, Schlitt HJ, Schnitzbauer AA. Is resection or transplantation the ideal treatment in patients with hepatocellular carcinoma in cirrhosis if both are possible? A systematic review and metaanalysis. *Ann Surg Oncol* 2014; **21**: 3096-3107 [PMID: 24866437 DOI: 10.1245/s10434-014-3808-1]

19 **Dagher I**, O'Rourke N, Geller DA, Cherqui D, Belli G, Gamblin TC, Lainas P, Laurent A, Nguyen KT, Marvin MR, Thomas M, Ravindra K, Fielding G, Franco D, Buell JF. Laparoscopic major hepatectomy: an evolution in standard of care. *Ann Surg* 2009; **250**: 856-860 [PMID: 19806057 DOI: 10.1097/SLA.0b013e3181bcaf46]

20 **Kluger MD**, Cherqui D. Laparoscopic resection of hepatocellular carcinoma. *Recent Results Cancer Res* 2013; **190**: 111-126 [PMID: 22941017 DOI: 10.1007/978-3-642-16037-0\_8]

21 **Xiong JJ**, Altaf K, Javed MA, Huang W, Mukherjee R, Mai G, Sutton R, Liu XB, Hu WM. Meta-analysis of laparoscopic vs open liver resection for hepatocellular carcinoma. *World J Gastroenterol* 2012; **18**: 6657-6668 [PMID: 23236242 DOI: 10.3748/wjg.v18.i45.6657]

22 **Zhou YM**, Shao WY, Zhao YF, Xu DH, Li B. Meta-analysis of laparoscopic versus open resection for hepatocellular carcinoma. *Dig Dis Sci* 2011; **56**: 1937-1943 [PMID: 21259071 DOI: 10.1007/s10620-011-1572-7]

23 **Reddy SK**, Tsung A, Geller DA. Laparoscopic liver resection. *World J Surg* 2011; **35**: 1478-1486 [PMID: 21181472 DOI: 10.1007/s00268-010-0906-5]

24 **Belli G**, Fantini C, Belli A, Limongelli P. Laparoscopic liver resection for hepatocellular carcinoma in cirrhosis: long-term outcomes. *Dig Surg* 2011; **28**: 134-140 [PMID: 21540599 DOI: 10.1159/000323824]

25 **Tranchart H**, Di Giuro G, Lainas P, Roudie J, Agostini H, Franco D, Dagher I. Laparoscopic resection for hepatocellular carcinoma: a matched-pair comparative study. *Surg Endosc* 2010; **24**: 1170-1176 [PMID: 19915908 DOI: 10.1007/s00464-009-0745-3]

26 **Lai EC**, Tang CN, Ha JP, Li MK. Laparoscopic liver resection for hepatocellular carcinoma: ten-year experience in a single center. *Arch Surg* 2009; **144**: 143-17; discussion 148 [PMID: 19221325 DOI: 10.1001/archsurg.2008.536]

27 **Bryant R**, Laurent A, Tayar C, van Nhieu JT, Luciani A, Cherqui D. Liver resection for hepatocellular carcinoma. *Surg Oncol Clin N Am* 2008; **17**: 607-33, ix [PMID: 18486886 DOI: 10.1016/j.soc.2008.02.002]

28 **Dagher I**, Belli G, Fantini C, Laurent A, Tayar C, Lainas P, Tranchart H, Franco D, Cherqui D. Laparoscopic hepatectomy for hepatocellular carcinoma: a European experience. *J Am Coll Surg* 2010; **211**: 16-23 [PMID: 20610244 DOI: 10.1016/j.jamcollsurg.2010.03.012]

29 **Aldrighetti L**, Guzzetti E, Pulitanò C, Cipriani F, Catena M, Paganelli M, Ferla G. Case-matched analysis of totally laparoscopic versus open liver resection for HCC: short and middle term results. *J Surg Oncol* 2010; **102**: 82-86 [PMID: 20578084 DOI: 10.1002/jso.21541]

30 **Kim SJ**, Jung HK, Lee DS, Yun SS, Kim HJ. The comparison of oncologic and clinical outcomes of laparoscopic liver resection for hepatocellular carcinoma. *Ann Surg Treat Res* 2014; **86**: 61-67 [PMID: 24761410 DOI: 10.4174/astr.2014.86.2.61]

31 **Zhou XD**. Recurrence and metastasis of hepatocellular carcinoma: progress and prospects. *Hepatobiliary Pancreat Dis Int* 2002; **1**: 35-41 [PMID: 14607620]

32 **Hasegawa K**, Kokudo N, Imamura H, Matsuyama Y, Aoki T, Minagawa M, Sano K, Sugawara Y, Takayama T, Makuuchi M. Prognostic impact of anatomic resection for hepatocellular carcinoma. *Ann Surg* 2005; **242**: 252-259 [PMID: 16041216]

33 **Cucchetti A**, Cescon M, Ercolani G, Bigonzi E, Torzilli G, Pinna AD. A comprehensive meta-regression analysis on outcome of anatomic resection versus nonanatomic resection for hepatocellular carcinoma. *Ann Surg Oncol* 2012; **19**: 3697-3705 [PMID: 22722807 DOI: 10.1245/s10434-012-2450-z]

34 **Cucchetti A**, Qiao GL, Cescon M, Li J, Xia Y, Ercolani G, Shen F, Pinna AD. Anatomic versus nonanatomic resection in cirrhotic patients with early hepatocellular carcinoma. *Surgery* 2014; **155**: 512-521 [PMID: 24439747 DOI: 10.1016/j.surg.2013.10.009]

35 **Tomimaru Y**, Eguchi H, Marubashi S, Wada H, Kobayashi S, Tanemura M, Umeshita K, Doki Y, Mori M, Nagano H. Equivalent outcomes after anatomical and non-anatomical resection of small hepatocellular carcinoma in patients with preserved liver function. *Dig Dis Sci* 2012; **57**: 1942-1948 [PMID: 22407377 DOI: 10.1007/s10620-012-2114-7]

36 **Yamamoto Y**, Ikoma H, Morimura R, Konishi H, Murayama Y, Komatsu S, Shiozaki A, Kuriu Y, Kubota T, Nakanishi M, Ichikawa D, Fujiwara H, Okamoto K, Sakakura C, Ochiai T, Otsuji E. Clinical analysis of anatomical resection for the treatment of hepatocellular carcinoma based on the stratification of liver function. *World J Surg* 2014; **38**: 1154-1163 [PMID: 24305927 DOI: 10.1007/s00268-013-2369-y]

37 **Shi M**, Guo RP, Lin XJ, Zhang YQ, Chen MS, Zhang CQ, Lau WY, Li JQ. Partial hepatectomy with wide versus narrow resection margin for solitary hepatocellular carcinoma: a prospective randomized trial. *Ann Surg* 2007; **245**: 36-43 [PMID: 17197963 DOI: 10.1097/01.sla.0000231758.07868.71]

38 **Zhou Y**, Xu D, Wu L, Li B. Meta-analysis of anatomic resection versus nonanatomic resection for hepatocellular carcinoma. *Langenbecks Arch Surg* 2011; **396**: 1109-1117 [PMID: 21476060 DOI: 10.1007/s00423-011-0784-9]

39 **Tung-Ping Poon R**, Fan ST, Wong J. Risk factors, prevention, and management of postoperative recurrence after resection of hepatocellular carcinoma. *Ann Surg* 2000; **232**: 10-24 [PMID: 10862190]

40 **Roayaie S**, Bassi D, Tarchi P, Labow D, Schwartz M. Second hepatic resection for recurrent hepatocellular cancer: a Western experience. *J Hepatol* 2011; **55**: 346-350 [PMID: 21147184 DOI: 10.1016/j.jhep.2010.11.026]

41 **Chan AC**, Poon RT, Chok KS, Cheung TT, Chan SC, Lo CM. Feasibility of laparoscopic re-resection for patients with recurrent hepatocellular carcinoma. *World J Surg* 2014; **38**: 1141-1146 [PMID: 24305932 DOI: 10.1007/s00268-013-2380-3]

42 **Ho CM**, Lee PH, Shau WY, Ho MC, Wu YM, Hu RH. Survival in patients with recurrent hepatocellular carcinoma after primary hepatectomy: comparative effectiveness of treatment modalities. *Surgery* 2012; **151**: 700-709 [PMID: 22284764 DOI: 10.1016/j.surg.2011.12.015]

43 **Forner A**, Llovet JM, Bruix J. Hepatocellular carcinoma. *Lancet* 2012; **379**: 1245-1255 [PMID: 22353262 DOI: 10.1016/S0140-6736(11)61347-0]

44 **Vitale A**, Morales RR, Zanus G, Farinati F, Burra P, Angeli P, Frigo AC, Del Poggio P, Rapaccini G, Di Nolfo MA, Benvegnù L, Zoli M, Borzio F, Giannini EG, Caturelli E, Chiaramonte M, Trevisani F, Cillo U. Barcelona Clinic Liver Cancer staging and transplant survival benefit for patients with hepatocellular carcinoma: a multicentre, cohort study. *Lancet Oncol* 2011; **12**: 654-662 [PMID: 21684210 DOI: 10.1016/S1470-2045(11)70144-9]

45 **Llovet JM**, Bustamante J, Castells A, Vilana R, Ayuso Mdel C, Sala M, Brú C, Rodés J, Bruix J. Natural history of untreated nonsurgical hepatocellular carcinoma: rationale for the design and evaluation of therapeutic trials. *Hepatology* 1999; **29**: 62-67 [PMID: 9862851 DOI: 10.1002/hep.510290145]

46 **Chok KS**, Cheung TT, Chan SC, Poon RT, Fan ST, Lo CM. Surgical outcomes in hepatocellular carcinoma patients with portal vein tumor thrombosis. *World J Surg* 2014; **38**: 490-496 [PMID: 24132826 DOI: 10.1007/s00268-013-2290-4]

47 **Pawlik TM**, Poon RT, Abdalla EK, Ikai I, Nagorney DM, Belghiti J, Kianmanesh R, Ng IO, Curley SA, Yamaoka Y, Lauwers GY, Vauthey JN. Hepatectomy for hepatocellular carcinoma with major portal or hepatic vein invasion: results of a multicenter study. *Surgery* 2005; **137**: 403-410 [PMID: 15800485 DOI: 10.1016/j.surg.2004.12.012]

48 **Arnaoutakis DJ**, Mavros MN, Shen F, Alexandrescu S, Firoozmand A, Popescu I, Weiss M, Wolfgang CL, Choti MA, Pawlik TM. Recurrence patterns and prognostic factors in patients with hepatocellular carcinoma in noncirrhotic liver: a multi-institutional analysis. *Ann Surg Oncol* 2014; **21**: 147-154 [PMID: 23959056 DOI: 10.1245/s10434-013-3211-3]

49 **Kim WR**, Stock PG, Smith JM, Heimbach JK, Skeans MA, Edwards EB, Harper AM, Snyder JJ, Israni AK, Kasiske BL. OPTN/SRTR 2011 Annual Data Report: liver. *Am J Transplant* 2013; **13** Suppl 1: 73-102 [PMID: 23237697 DOI: 10.1111/ajt.12021]

50 **Lim KC,** Wang VW, Siddiqui FJ, Shi L, Chan ES, Oh HC, Tan SB, Chow PK. Cost-effectiveness analysis of liver resection versus transplantation for early hepatocellular carcinoma within the Milan criteria. *Hepatology* 2014; [PMID: 24638991 DOI: 10.1002/hep.27135]

51 **Mazzaferro V**, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F, Montalto F, Ammatuna M, Morabito A, Gennari L. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. *N Engl J Med* 1996; **334**: 693-699 [PMID: 8594428 DOI: 10.1056/NEJM199603143341104]

52 **Yao FY**, Ferrell L, Bass NM, Watson JJ, Bacchetti P, Venook A, Ascher NL, Roberts JP. Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival. *Hepatology* 2001; **33**: 1394-1403 [PMID: 11391528 DOI: 10.1053/jhep.2001.24563]

53 **Toso C**, Trotter J, Wei A, Bigam DL, Shah S, Lancaster J, Grant DR, Greig PD, Shapiro AM, Kneteman NM. Total tumor volume predicts risk of recurrence following liver transplantation in patients with hepatocellular carcinoma. *Liver Transpl* 2008; **14**: 1107-1115 [PMID: 18668667 DOI: 10.1002/lt.21484]

54 **Mazzaferro V**, Llovet JM, Miceli R, Bhoori S, Schiavo M, Mariani L, Camerini T, Roayaie S, Schwartz ME, Grazi GL, Adam R, Neuhaus P, Salizzoni M, Bruix J, Forner A, De Carlis L, Cillo U, Burroughs AK, Troisi R, Rossi M, Gerunda GE, Lerut J, Belghiti J, Boin I, Gugenheim J, Rochling F, Van Hoek B, Majno P. Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. *Lancet Oncol* 2009; **10**: 35-43 [PMID: 19058754 DOI: 10.1016/S1470-2045(08)70284-5]

55 **Lee SG**, Hwang S, Moon DB, Ahn CS, Kim KH, Sung KB, Ko GY, Park KM, Ha TY, Song GW. Expanded indication criteria of living donor liver transplantation for hepatocellular carcinoma at one large-volume center. *Liver Transpl* 2008; **14**: 935-945 [PMID: 18581465 DOI: 10.1002/lt.21445]

56 **Chen JW**, Kow L, Verran DJ, McCall JL, Munn S, Balderson GA, Fawcett JW, Gow PJ, Jones RM, Jeffrey GP, House AK, Strasser SI. Poorer survival in patients whose explanted hepatocellular carcinoma (HCC) exceeds Milan or UCSF Criteria. An analysis of liver transplantation in HCC in Australia and New Zealand. *HPB* (Oxford) 2009; **11**: 81-89 [PMID: 19590628 DOI: 10.1111/j.1477-2574.2009.00022.x]

57 **DuBay D**, Sandroussi C, Sandhu L, Cleary S, Guba M, Cattral MS, McGilvray I, Ghanekar A, Selzner M, Greig PD, Grant DR. Liver transplantation for advanced hepatocellular carcinoma using poor tumor differentiation on biopsy as an exclusion criterion. *Ann Surg* 2011; **253**: 166-172 [PMID: 21294289]

58 **Herrero JI**, Sangro B, Quiroga J, Pardo F, Herraiz M, Cienfuegos JA, Prieto J. Influence of tumor characteristics on the outcome of liver transplantation among patients with liver cirrhosis and hepatocellular carcinoma. *Liver Transpl* 2001; **7**: 631-636 [PMID: 11460231 DOI: 10.1053/jlts.2001.25458]

59 **Ito T**, Takada Y, Ueda M, Haga H, Maetani Y, Oike F, Ogawa K, Sakamoto S, Ogura Y, Egawa H, Tanaka K, Uemoto S. Expansion of selection criteria for patients with hepatocellular carcinoma in living donor liver transplantation. *Liver Transpl* 2007; **13**: 1637-1644 [PMID: 18044766 DOI: 10.1002/lt.21281]

60 **Ravaioli M**, Grazi GL, Piscaglia F, Trevisani F, Cescon M, Ercolani G, Vivarelli M, Golfieri R, D'Errico Grigioni A, Panzini I, Morelli C, Bernardi M, Bolondi L, Pinna AD. Liver transplantation for hepatocellular carcinoma: results of down-staging in patients initially outside the Milan selection criteria. *Am J Transplant* 2008; **8**: 2547-2557 [PMID: 19032223 DOI: 10.1111/j.1600-6143.2008.02409.x]

61 **Forner A**, Reig ME, de Lope CR, Bruix J. Current strategy for staging and treatment: the BCLC update and future prospects. *Semin Liver Dis* 2010; **30**: 61-74 [PMID: 20175034 DOI: 10.1055/s-0030-1247133]

62 **Torzilli G**, Donadon M, Marconi M, Palmisano A, Del Fabbro D, Spinelli A, Botea F, Montorsi M. Hepatectomy for stage B and stage C hepatocellular carcinoma in the Barcelona Clinic Liver Cancer classification: results of a prospective analysis. *Arch Surg* 2008; **143**: 1082-1090 [PMID: 19015467 DOI: 10.1001/archsurg.143.11.1082]

63 **Ruzzenente A**, Capra F, Pachera S, Iacono C, Piccirillo G, Lunardi M, Pistoso S, Valdegamberi A, D'Onofrio M, Guglielmi A. Is liver resection justified in advanced hepatocellular carcinoma? Results of an observational study in 464 patients. *J Gastrointest Surg* 2009; **13**: 1313-1320 [PMID: 19418103 DOI: 10.1007/s11605-009-0903-x]

64 **Huang J**, Yan L, Cheng Z, Wu H, Du L, Wang J, Xu Y, Zeng Y. A randomized trial comparing radiofrequency ablation and surgical resection for HCC conforming to the Milan criteria. *Ann Surg* 2010; **252**: 903-912 [PMID: 21107100 DOI: 10.1097/SLA.0b013e3181efc656]

65 **Hasegawa K**, Makuuchi M, Takayama T, Kokudo N, Arii S, Okazaki M, Okita K, Omata M, Kudo M, Kojiro M, Nakanuma Y, Takayasu K, Monden M, Matsuyama Y, Ikai I. Surgical resection vs. percutaneous ablation for hepatocellular carcinoma: a preliminary report of the Japanese nationwide survey. *J Hepatol* 2008; **49**: 589-594 [PMID: 18620773 DOI: 10.1016/j.jhep.2008.05.018]

66 **Poon RT**, Fan ST, Lo CM, Liu CL, Wong J. Long-term survival and pattern of recurrence after resection of small hepatocellular carcinoma in patients with preserved liver function: implications for a strategy of salvage transplantation. *Ann Surg* 2002; **235**: 373-382 [PMID: 11882759]

67 **Majno PE**, Sarasin FP, Mentha G, Hadengue A. Primary liver resection and salvage transplantation or primary liver transplantation in patients with single, small hepatocellular carcinoma and preserved liver function: an outcome-oriented decision analysis. *Hepatology* 2000; **31**: 899-906 [PMID: 10733546 DOI: 10.1053/he.2000.5763]

68 **Belghiti J**, Cortes A, Abdalla EK, Régimbeau JM, Prakash K, Durand F, Sommacale D, Dondero F, Lesurtel M, Sauvanet A, Farges O, Kianmanesh R. Resection prior to liver transplantation for hepatocellular carcinoma. *Ann Surg* 2003; **238**: 885-92; discussion 892-3 [PMID: 14631225 DOI: 10.1097/01.sla.0000098621.74851.65]

69 **Adam R**, Azoulay D, Castaing D, Eshkenazy R, Pascal G, Hashizume K, Samuel D, Bismuth H. Liver resection as a bridge to transplantation for hepatocellular carcinoma on cirrhosis: a reasonable strategy? *Ann Surg* 2003; **238**: 508-18; discussion 518-9 [PMID: 14530722 DOI: 10.1097/01.sla.0000090449.87109.44]

70 **Del Gaudio M**, Ercolani G, Ravaioli M, Cescon M, Lauro A, Vivarelli M, Zanello M, Cucchetti A, Vetrone G, Tuci F, Ramacciato G, Grazi GL, Pinna AD. Liver transplantation for recurrent hepatocellular carcinoma on cirrhosis after liver resection: University of Bologna experience. *Am J Transplant* 2008; **8**: 1177-1185 [PMID: 18444925 DOI: 10.1111/j.1600-6143.2008.02229.x]

71 **Sala M**, Fuster J, Llovet JM, Navasa M, Solé M, Varela M, Pons F, Rimola A, García-Valdecasas JC, Brú C, Bruix J. High pathological risk of recurrence after surgical resection for hepatocellular carcinoma: an indication for salvage liver transplantation. *Liver Transpl* 2004; **10**: 1294-1300 [PMID: 15376311 DOI: 10.1002/lt.20202]

72 **Fuks D**, Durand F, Belghiti J. The role of biopsy of the nontumorous liver parenchyma in patients considered for partial resection of small hepatocellular carcinoma. *Hepatology* 2013; **58**: 452 [PMID: 23315837 DOI: 10.1002/hep.26244]

73 **Belghiti J**, Carr BI, Greig PD, Lencioni R, Poon RT. Treatment before liver transplantation for HCC. *Ann Surg Oncol* 2008; **15**: 993-1000 [PMID: 18236111 DOI: 10.1245/s10434-007-9787-8]

74 **Cherqui D**, Laurent A, Mocellin N, Tayar C, Luciani A, Van Nhieu JT, Decaens T, Hurtova M, Memeo R, Mallat A, Duvoux C. Liver resection for transplantable hepatocellular carcinoma: long-term survival and role of secondary liver transplantation. *Ann Surg* 2009; **250**: 738-746 [PMID: 19801927 DOI: 10.1097/SLA.0b013e3181bd582b]

75 **Buell JF**, Cherqui D, Geller DA, O'Rourke N, Iannitti D, Dagher I, Koffron AJ, Thomas M, Gayet B, Han HS, Wakabayashi G, Belli G, Kaneko H, Ker CG, Scatton O, Laurent A, Abdalla EK, Chaudhury P, Dutson E, Gamblin C, D'Angelica M, Nagorney D, Testa G, Labow D, Manas D, Poon RT, Nelson H, Martin R, Clary B, Pinson WC, Martinie J, Vauthey JN, Goldstein R, Roayaie S, Barlet D, Espat J, Abecassis M, Rees M, Fong Y, McMasters KM, Broelsch C, Busuttil R, Belghiti J, Strasberg S, Chari RS. The international position on laparoscopic liver surgery: The Louisville Statement, 2008. *Ann Surg* 2009; **250**: 825-830 [PMID: 19916210]

76 **Giannini EG**, Cucchetti A, Vitale A. Prognostic prediction and identification of candidates for salvage liver transplantation among patients with early hepatocellular carcinoma. *Liver Transpl* 2014; **20**: 1150-1151 [PMID: 24916303 DOI: 10.1002/lt.23927]

77 **Chan DL**, Alzahrani NA, Morris DL, Chua TC. Systematic review of efficacy and outcomes of salvage liver transplantation after primary hepatic resection for hepatocellular carcinoma. *J Gastroenterol Hepatol* 2014; **29**: 31-41 [PMID: 24117517 DOI: 10.1111/jgh.12399]

78 **Becker JM**, Dayton MT, Fazio VW, Beck DE, Stryker SJ, Wexner SD, Wolff BG, Roberts PL, Smith LE, Sweeney SA, Moore M. Prevention of postoperative abdominal adhesions by a sodium hyaluronate-based bioresorbable membrane: a prospective, randomized, double-blind multicenter study. *J Am Coll Surg* 1996; **183**: 297-306 [PMID: 8843257]

79 **Perkins JD**. Is there any benefit to laparoscopic liver resection for hepatocellular carcinoma if a salvage liver transplant is needed later? *Liver Transpl* 2009; **15**: 813-814 [PMID: 19582953]

80 **Laurent A**, Tayar C, Andréoletti M, Lauzet JY, Merle JC, Cherqui D. Laparoscopic liver resection facilitates salvage liver transplantation for hepatocellular carcinoma. *J Hepatobiliary Pancreat Surg* 2009; **16**: 310-314 [PMID: 19280110 DOI: 10.1007/s00534-009-0063-0]

81 **Qu W,** Zhu ZJ, Sun LY, Wei L, Liu Y, Zeng ZG. Salvage liver transplantation for hepatocellular carcinoma recurrence after primary liver resection. *Clin Res Hepatol Gastroenterol* 2014; [PMID: 25150375 DOI: 10.1016/j.clinre.2014.07.006]

**P-Reviewer:** Robles R **S-Editor:** Qi Y **L-Editor: E-Editor:**